CombiPatch and Climara Pro: FDA Approval, Label Details, Safety, and Legal & Patent History

What Are CombiPatch and Climara Pro, and Why Do They Matter for Menopausal Women?

CombiPatch and Climara Pro are transdermal patches that deliver estradiol plus a progestin in a single adhesive system. For women in perimenopause or post-menopause who still have a uterus, combining a progestin with systemic estrogen is not optional. Estrogen alone raises the risk of endometrial hyperplasia and carcinoma, so progestin opposition is required. These patches handle that obligation in one application, which many women find easier than managing separate preparations.

The two patches differ in their progestin. CombiPatch uses norethindrone acetate (NETA), a 19-nortestosterone derivative with some androgenic activity. Climara Pro uses levonorgestrel (LNG), which is also androgenic but at a much lower daily transdermal dose. The clinical significance of this difference for an individual woman is modest at standard doses, though women with androgen-sensitive conditions such as acne or hirsutism sometimes notice a difference.

The Transdermal Route and Why It Differs from Oral HRT

Transdermal estradiol bypasses first-pass hepatic metabolism. That matters because oral estrogens raise sex-hormone-binding globulin (SHBG), triglycerides, and C-reactive protein in ways that transdermal preparations largely avoid. A 2007 case-control study published in Circulation found that oral but not transdermal estrogen was associated with elevated VTE risk, a finding replicated in multiple observational cohorts. The ESTHER study, which specifically compared oral and transdermal estrogen in French post-menopausal women, found no increase in VTE with transdermal use but a statistically significant increase with oral preparations published in Circulation 2007.

Progestins in transdermal patches also reach lower systemic concentrations than oral progestogens, which may translate to a different metabolic and breast-tissue exposure profile. This is an area where the evidence base in women is genuinely thin; most large randomized trials used oral progestogens, not transdermal combinations, so some extrapolation is unavoidable.

Life-Stage Context: Who Is This Drug For?

• Perimenopause. Vasomotor symptoms, irregular bleeding, and sleep disruption are common. If systemic therapy is chosen and the uterus is intact, a combination patch is one reasonable approach. Irregular bleeding is expected early in perimenopause regardless of HRT; starting a continuous combined patch in late perimenopause typically reduces but does not eliminate irregular spotting for the first 3-6 months.
• Post-menopause. Continuous combined transdermal HRT achieves amenorrhea in most women within 6 months and is the most studied life-stage for these products.
• Surgical menopause (hysterectomy). Women who have had a hysterectomy do NOT need a progestin. A combination patch is unnecessary and exposes them to progestin risks without endometrial benefit. An estrogen-only patch is appropriate.
• Trying to conceive or pregnant. These patches are contraindicated. Full detail in the pregnancy section below.

FDA Approval History and Regulatory Milestones

CombiPatch: Approved 1998

The FDA approved CombiPatch on February 26, 1998, under NDA 020903. The original manufacturer was Noven Pharmaceuticals, which developed the drug-in-adhesive matrix technology. Marketing rights were held by Novartis at launch and subsequently transferred. The Drugs@FDA record for NDA 020903 documents the approval letter, labeling history, and all subsequent supplements.

CombiPatch is available in two dose strengths:

| Patch | Estradiol | Norethindrone Acetate | Change Schedule | |---|---|---|---| | CombiPatch 0.05/0.14 | 0.05 mg/day | 0.14 mg/day | Twice weekly | | CombiPatch 0.05/0.25 | 0.05 mg/day | 0.25 mg/day | Twice weekly |

The key trial submitted to the FDA enrolled post-menopausal women with an intact uterus and demonstrated a statistically significant reduction in moderate-to-severe hot flushes versus placebo, with endometrial safety confirmed by biopsy at 12 months showing no cases of hyperplasia in the continuous combined group see the 2003 continuous combined transdermal HRT biopsy data at PubMed.

Climara Pro: Approved 2003

The FDA approved Climara Pro on May 23, 2003, under NDA 021372. Bayer HealthCare Pharmaceuticals is the originator. Climara Pro delivers estradiol 0.045 mg/day plus levonorgestrel 0.015 mg/day from a single once-weekly patch, differentiating it from CombiPatch's twice-weekly schedule. The Drugs@FDA record for NDA 021372 tracks every labeling supplement since 2003.

The once-weekly change schedule was a deliberate commercial and clinical design choice. Adherence data consistently show that weekly patch change is preferred over twice-weekly by most women in observational surveys, though no randomized head-to-head adherence trial between the two products has been published.

Post-Approval Labeling Changes and the Women's Health Initiative Effect

The Women's Health Initiative (WHI), whose initial oral CE/MPA results were published in JAMA in 2002, triggered mandatory labeling revisions across all systemic HRT products. The FDA issued a Black Box Warning requirement in January 2003. Both CombiPatch and Climara Pro received updated labels adding the cardiovascular, stroke, VTE, breast cancer, and dementia (in women 65 and older) warnings derived primarily from the WHI data.

The WHI used oral conjugated equine estrogens plus medroxyprogesterone acetate, not transdermal estradiol plus NETA or LNG. Applying those risk figures to transdermal combination patches is an extrapolation. The current ACOG Practice Bulletin on hormone therapy (reaffirmed 2022) and The Menopause Society (NAMS) 2022 Position Statement both acknowledge that transdermal estrogen carries a lower thrombotic signal than oral preparations and that the WHI cannot be directly extrapolated to all HRT formulations.

A practical framework: when a post-menopausal woman asks you which patch differs less from WHI-derived risk estimates, the honest answer is that both transdermal combination patches lack large randomized trial data of their own, but the observational signal for transdermal estradiol and VTE is consistently reassuring, and the progestin dose in both patches is substantially lower than the 2.5 mg/day oral MPA used in the WHI.

What the Current Label Says: Key Safety Information for Women

Black-Box Warnings

The FDA-approved label for both products carries class-wide black-box warnings for:

1. Cardiovascular events. Increased risk of MI, stroke, and deep vein thrombosis. Risk is increased in women who smoke, are over 60, or who are more than 10 years past menopause onset. The 2022 NAMS position statement recommends initiating HRT within 10 years of menopause onset or before age 60 to stay within the window where cardiovascular risk is most favorable.
2. Breast cancer. The label cites the WHI finding that combined estrogen-progestin therapy increased breast cancer incidence by approximately 26% (HR 1.26, 95% CI 1.00-1.59) after a mean 5.6 years. Estrogen-only therapy in the WHI hysterectomy cohort did not increase breast cancer risk over 7.1 years, which underscores that the progestin component contributes substantially to breast risk in combined regimens.
3. Dementia. In the WHIMS substudy of women 65 and older, combined HRT was associated with approximately doubled risk of probable dementia. This signal is specific to the older age group and is not established in women under 65 initiating HRT close to menopause.
4. Endometrial cancer. The label specifies that progestin is included to reduce this risk. Unopposed estrogen is listed as contraindicated in women with an intact uterus.

Contraindications Listed on the Label

The label contraindicates use in women with:

• Undiagnosed abnormal uterine bleeding
• Known or suspected breast cancer or a personal history of breast cancer
• Known or suspected estrogen-dependent neoplasia
• Active DVT, PE, or a history of these conditions
• Active arterial thromboembolic disease (recent MI or stroke)
• Liver dysfunction or disease
• Known hypersensitivity to any patch component
• Known or suspected pregnancy

Progestin-Specific Considerations: NETA vs. LNG in Women

Both NETA and LNG are androgenic progestins. In clinical practice this matters most for women with:

• PCOS. Androgenic progestins may theoretically worsen androgen-related symptoms. Women with PCOS who reach perimenopause or post-menopause and need HRT may prefer a less androgenic progestin such as micronized progesterone, though systemic transdermal absorption of the progestin in these patches is lower than with oral preparations, somewhat attenuating this concern.
• Acne or seborrhea. A minority of women report worsening skin symptoms on androgenic progestins.
• Lipid profiles. LNG and NETA can reduce HDL and raise LDL slightly compared to progesterone. At the doses delivered transdermally by these patches, the effect is generally small, but women with dyslipidemia warrant a lipid check at baseline and 6-12 months after starting.

Patent History and Legal Challenges

Noven's Drug-in-Adhesive Technology

CombiPatch's commercial history is inseparable from Noven Pharmaceuticals' matrix transdermal technology patents. Noven pioneered the drug-in-adhesive (DIA) patch platform in the 1980s and 1990s, holding patents covering both the manufacturing process and the specific polymer matrix used to incorporate hormones without a rate-controlling membrane. These patents were the basis for multiple licensing agreements and litigation episodes involving generic manufacturers.

The key Noven patents covering CombiPatch were filed in the mid-1990s. Their expiry opened the door to Paragraph IV ANDA (Abbreviated New Drug Application) challenges under the Hatch-Waxman Act, in which generic manufacturers certify that the originator's patents are either invalid or not infringed by their product. Several generic ANDAs for estradiol/norethindrone acetate patches were filed with the FDA, triggering the standard 30-month stay of generic approval while litigation proceeded. Generic combination estradiol/NETA patches entered the U.S. Market following resolution of those disputes and patent expiration.

Bayer and Climara Pro Patent Field

Climara Pro's patents covered the once-weekly estradiol/LNG matrix formulation. Bayer faced ANDA challenges from multiple generic filers, with Paragraph IV certifications asserting invalidity or non-infringement of the formulation patents. The 30-month stays associated with those filings delayed generic entry. Following expiration of the primary formulation patents, generic estradiol/levonorgestrel patches received FDA approval, and Drugs@FDA lists the approved ANDA holders for both reference listed drugs.

The public record does not document any unique, publicly litigated court opinions regarding Climara Pro that rose to appellate prominence in the way that some other hormone patch cases did. The disputes followed the standard Hatch-Waxman structure: ANDA filing, Paragraph IV certification, 30-month stay, district court litigation, and eventual resolution either by settlement (which is common and often involves authorized generic or licensing arrangements) or by a court finding on validity and infringement.

What Generic Entry Means for You

Generic combination patches are therapeutically equivalent to their reference listed drugs under FDA's substitution standards. The FDA requires that a generic transdermal patch demonstrate bioequivalence through pharmacokinetic studies showing that estradiol and progestin area-under-the-curve (AUC) and peak concentration (Cmax) fall within the standard 80-125% confidence interval boundaries. If your pharmacy substitutes a generic, it is FDA-verified to deliver essentially the same hormone exposure.

One practical caveat: adhesive formulations can differ between brand and generic, and a small number of women report differences in skin adhesion, irritation, or patch wear. If you switch from brand to generic (or between generics) and notice a change in bleeding pattern or symptom control, check with your clinician before assuming a clinical failure.

Pregnancy, Lactation, and Contraception: Required Reading

CombiPatch and Climara Pro are contraindicated in pregnancy. Both products contain progestins with androgenic activity, and fetal exposure to androgens carries teratogenic risk. Sex hormone-containing medications as a class have been associated with masculinization of female fetuses and other congenital anomalies in case reports, though causality for individual exposures is difficult to establish.

Pregnancy Category and Human Data

Under the legacy FDA pregnancy category system, estrogen-progestin combinations were classified as Category X, meaning that the risks clearly outweigh any possible benefit in pregnancy and the drugs are contraindicated. The FDA's current Pregnancy and Lactation Labeling Rule (PLLR), which replaced letter categories for drugs approved or relabeled after June 2015, requires a narrative summary of available human and animal data. The current labels for both patches state that there are no adequate and well-controlled studies in pregnant women and that the drugs should not be used during pregnancy. The FDA's PLLR guidance is available at FDA.gov.

Perimenopause and the Contraception Requirement

Perimenopause is not infertility. Ovulation can occur sporadically until menopause is confirmed (12 consecutive months of amenorrhea). A woman in early or mid-perimenopause using a combination HRT patch is not protected against pregnancy by the patch itself. The progestin dose in these patches is far below the ovulation-suppressing doses used in contraceptive pills or the hormonal IUD.

If you are in perimenopause, still potentially ovulating, and starting a combination HRT patch, you need a separate, reliable contraceptive method. Options commonly discussed with a clinician include:

• Low-dose combined oral contraceptive pill (which also manages perimenopausal symptoms)
• Progestin-only IUD (Mirena is also FDA-approved for heavy menstrual bleeding)
• Barrier methods

ACOG recommends that women use contraception until 12 months of amenorrhea confirm post-menopausal status.

Lactation

Estrogen suppresses milk production. Combination estrogen-progestin patches are not appropriate for breastfeeding women. If you are postpartum and breastfeeding, systemic estrogen-containing HRT should be deferred until lactation ends. Progestin-only contraception is compatible with lactation and does not suppress milk supply at standard doses, but that is a separate category of drug from these HRT patches. The Academy of Breastfeeding Medicine provides detailed guidance on hormonal contraception and lactation.

Who Is a Good Candidate for a Combination Patch, and Who Is Not?

Women Who May Benefit

• Post-menopausal women with an intact uterus who have moderate-to-severe vasomotor symptoms (hot flushes, night sweats)
• Women who cannot tolerate oral HRT due to gastrointestinal side effects or migraines with aura (where estrogen-containing oral pills carry a stroke risk signal)
• Women who prefer a lower pill burden and find a patch more convenient than daily oral pills
• Women who have elevated triglycerides at baseline (transdermal estrogen does not raise triglycerides the way oral estrogen does)
• Women within 10 years of menopause onset or under age 60 who are in the favorable timing window described in the NAMS 2022 position statement

Women for Whom a Combination Patch Is Typically Not Appropriate

• Women who have had a hysterectomy (no uterus means no need for progestin; estrogen-only is sufficient and avoids progestin risks)
• Women with a personal history of breast cancer (contraindicated per label; discuss risk with your oncologist and gynecologist together)
• Women with a history of VTE or stroke (the thrombotic risk in the label contraindicates use)
• Pregnant women or those trying to conceive
• Women with active liver disease
• Women over 60 initiating HRT for the first time more than 10 years after their last menstrual period, where the cardiovascular risk-benefit ratio is less favorable
• Women with undiagnosed uterine bleeding (needs evaluation before starting)

Female-Specific Conditions That Intersect With This Drug

• PCOS. Women with PCOS reaching perimenopause may have persistent insulin resistance and dyslipidemia. The androgenic progestins in these patches may have a small unfavorable lipid effect; baseline labs are warranted.
• Endometriosis. The progestin component may reduce endometriosis-related pain in post-menopausal women, but evidence for this specific benefit with transdermal combination patches is limited.
• Osteoporosis. Both patches are FDA-approved for prevention of post-menopausal osteoporosis. Estradiol preserves bone mineral density. A Cochrane review of HRT and bone density confirmed that HRT reduces fracture risk in post-menopausal women, though it is not a first-line fracture treatment when dedicated bone agents (bisphosphonates, denosumab) are indicated.
• Female sexual dysfunction and GSM. Systemic estrogen from these patches may improve genitourinary syndrome of menopause (GSM) symptoms, though local vaginal estrogen is more targeted for that indication and does not carry the same systemic risks.

Post-Market Surveillance and the FDA Sentinel System

Post-approval safety monitoring for both products falls under the FDA's Sentinel System, a distributed active surveillance network that links claims data from millions of insured Americans to identify drug safety signals. The FDA Sentinel System overview is at FDA.gov. No specific public Sentinel query results for CombiPatch or Climara Pro have been published as standalone reports, which is itself informative: the absence of a public Sentinel-triggered safety action since approval suggests no signal has crossed the regulatory threshold requiring a label change or market withdrawal for either product in the post-WHI era.

The pharmacovigilance record does include periodic label updates. The most significant post-approval change was the addition of the black-box warnings in 2003 following the WHI results. Subsequent supplements have addressed application site reactions, clarified the 10-year timing window language, and incorporated data from smaller observational studies. The Drugs@FDA supplement history for both NDAs is publicly searchable and shows the full chronology.

What Women Should Watch for and Report

Application site reactions (redness, irritation, contact dermatitis) are the most common adverse events specific to patches as a delivery system. Systemic adverse events to report promptly include:

• Sudden chest pain, shortness of breath, or leg pain/swelling (possible VTE or PE)
• New or sudden severe headache (possible stroke)
• Unusual vaginal bleeding after establishing amenorrhea
• Breast changes or new breast mass

Women experiencing any of these should seek immediate evaluation and not simply remove the patch and wait.